Navigation Links
Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets
Date:8/11/2009

PRINCETON, N.J., Aug. 11 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that RLL has received final approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), and 50 mg (base). The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drug Imitrex(R)* by GlaxoSmithKline. Total annual market sales for Sumatriptan Succinate 25 mg and 50 mg tablets were $379 million (IMS - MAT: June 2009) which is indicated for the acute treatment of migraine attacks with or without aura in adults.

"We are pleased to receive this final approval for Sumatriptan Succinate Tablets 25 mg and 50 mg in addition to the 100 mg that was previously approved. This FDA approval represents the sixth such authorization to commercialize product to be granted by the agency so far in 2009. This product will be launched immediately to all classes of trade and further expands our product portfolio of affordable generic product formulations, that will be of benefit to patients, healthcare professionals and the U.S. healthcare system," according to Bill Winter, Vice President, Trade Sales, North America.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries. Ranbaxy is a subsidiary of Daiichi Sankyo Company, Ltd.

*Imitrex(R) is a registered trademark of GlaxoSmithKline

    CONTACTS:

    Charles M. Caprariello                       Edwige Buteau
    Vice President, Corporate Communications     RF Binder Partners Inc.
    Ranbaxy Inc.                                 (212) 994-7517
    (609) 720-5615

                                                 Andrea Pavone
                                                 RF Binder Partners Inc.
                                                 (212) 994-7569


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets
2. Press Statement Issued by Ranbaxy Laboratories Limited
3. Cipher Pharmaceuticals announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN
4. Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide
5. Ranbaxy to Bring in Daiichi Sankyo as Majority Partner; Strategic Combination Creates Innovator and Generic Pharma Powerhouse
6. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution
7. Ranbaxy Gains Approval to Manufacture and Market Cefuroxime Axetil for Oral Suspension
8. Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Tablets (OTC), 5mg and 10mg
9. Ranbaxy Receives Tentative Approval For Valsartan Tablets
10. Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
11. Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the U.S. Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in ... a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular ... has leant his presence to an educational purpose as the host of the “Informed” ... being cancer. In a recent episode, the series focuses on thyroid cancer. , Although ...
(Date:4/27/2017)... ... 2017 , ... Healthcare companies are trying to meet talent shortages and find ... executive resume. , “If you’re a healthcare executive open to new opportunities this year ... as ready as you are for a new job search. I’ve heard from countless ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Goodcents Deli ... open in the Lincoln, Neb. area this year. , The first new location ... The second location will open at 84th and Northern Lights Drive this fall. And ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
Breaking Medicine Technology: